Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

Following Wegovy's success, Eli Lilly introduced Zepbound after receiving US Food and Drug Administration (FDA) approval in November 2023. Zepbound, also known as Mounjaro outside the US ...

Novo Nordisk’s obesity drug CagriSema’s test results showed an average weight loss of over 20%, but its stock slid in ...

A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.